Clinical Scorecard: Aflibercept 8 mg Meets Primary Endpoint in QUASAR
At a Glance
| Category | Detail |
|---|---|
| Condition | Macular edema secondary to retinal vein occlusion (RVO) |
| Key Mechanisms | Aflibercept 8 mg demonstrated noninferior vision gains with fewer injections compared to aflibercept 2 mg. |
| Target Population | Treatment-naïve patients with RVO |
| Care Setting | Ophthalmology clinics and retina specialist practices |
Key Highlights
- Aflibercept 8 mg achieved noninferior vision gains with fewer injections than 2 mg.
- Average injections at week 36: 6.1 for 8 mg vs. 8.8 for 2 mg.
- 70% of patients in the 8 mg group had dosing intervals of every 12 weeks.
- Safety profile of aflibercept 8 mg consistent with 2 mg, no new concerns.
- Anatomic improvements correlated with visual outcomes across RVO subtypes.
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and central retinal thickness in patients with RVO.
Management
- Consider aflibercept 8 mg for treatment-naïve patients with RVO.
Monitoring & Follow-up
- Monitor visual acuity and retinal thickness at regular intervals.
Risks
- Evaluate for potential adverse effects consistent with aflibercept use.
Patient & Prescribing Data
Over 800 patients across 27 countries in the QUASAR trial.
Aflibercept 8 mg reduces treatment burden without compromising efficacy.
Clinical Best Practices
- Utilize predefined dose regimen modification criteria for treatment intervals.
- Aim for extended dosing intervals to reduce patient burden.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.